Zachary Brumberger

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Purpose: Treatment options are limited for patients with high-risk myelodysplastic syndrome (MDS). The azanucleosides, azacitidine and decitabine, are first-line therapy for MDS that induce promoter(More)
  • 1